Skip to main content
. 2022 Sep 12;12:982948. doi: 10.3389/fonc.2022.982948

Table 3.

Rate of overall survival and progression free survival at 6 months and 12 months.

Rate, % TACE-LEN (N=52) TACE-LEN-C (N=31)
OS 6 months 88.2 96.7
OS 12 months 55.1 95.7
PFS 6 months 50 93.3
PFS 12 months 0 42.3

OS, overall survival; PFS, progression-free survival; TACE-LEN, transcatheter arterial chemoembolization with Lenvatinib; TACE-LEN-C, transcatheter arterial chemoembolization with Lenvatinib plus camrelizumab.